Guo Xiu-ying, Si Tong-guo, Guo Zhi, Wang Hai-tao
Department of Interventional Therapy, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China.
Zhonghua Yi Xue Za Zhi. 2010 Apr 13;90(14):952-5.
To assess the anti-tumor immune response of cryoablation for prostate cancer.
Mouse model of prostate cancer was established. And the tumor-bearing mice were divided into three groups: control group (Group A), surgery group (Group B) and cryoablation group (Group C). Blood samples were withdrawn before and at Days 7, 14, 21 post-treatment. IFN-gamma and IL-4 were analyzed by enzyme-linked immunosorbent assay (ELISA). Th1/Th2 ratio was estimated from the IFN-gamma/IL-4 ratio. Lymphocytes of draining lymph node (DLN) and spleen were isolated. And the post-therapeutical number of tumor-specific IFN-gamma+CD4+ Th cells was measured by the method of enzyme link immunological spot (ELISPOT). And tumor-specific cytolytic activity of CD8+ cytotoxic T lymphocyte (CTL) was measured by LDH assay. The rate of metastasis was assessed.
At Day 7 post-treatment in Groups A, B and C, Th1/Th2 ratio was 4.97+/-0.31, 10.07+/-0.62 and 13.71+/-0.57 respectively (P<0.05); the number of IFN-gamma+ cells every 10(6) CD4+ Th cells in DLN 22.3+/-1.0, 24.0+/-1.2 and 243.4+/-46.2 respectively; cytolytic activity of cytotoxic T lymphocyte against prostate cancer cells (14.6+/-1.1)%, (15.2+/-0.8)% and (62.6+/-2.3)% respectively (P<0.05). But for T cells derived from spleen, there were no difference in IFN-gamma+CD4+ Th cells or cytolytic activity of CTL among the groups. At Day 28 post-treatment, the rate of DLN metastasis was 100%, 80% and 40% respectively. And the rates of lung metastasis were all 100%.
Cryoablation for prostate cancer can induce the Th1 advantage of anti-tumor immunity and generate the tumor-specific immune response in DLN. But the response remains limited. Further studies are warranted.
评估前列腺癌冷冻消融的抗肿瘤免疫反应。
建立前列腺癌小鼠模型。将荷瘤小鼠分为三组：对照组（A组）、手术组（B组）和冷冻消融组（C组）。在治疗前及治疗后第7、14、21天采集血样。采用酶联免疫吸附测定（ELISA）法分析干扰素-γ（IFN-γ）和白细胞介素-4（IL-4）。根据IFN-γ/IL-4比值估算Th1/Th2比值。分离引流淋巴结（DLN）和脾脏的淋巴细胞。采用酶联免疫斑点法（ELISPOT）检测治疗后肿瘤特异性IFN-γ+CD4+ Th细胞数量。采用乳酸脱氢酶（LDH）测定法检测CD8+细胞毒性T淋巴细胞（CTL）的肿瘤特异性细胞溶解活性。评估转移率。
治疗后第7天，A、B、C组的Th1/Th2比值分别为4.97±0.31、10.07±0.62和13.71±0.57（P<0.05）；每10(6)个DLN中CD4+ Th细胞中IFN-γ+细胞数量分别为22.3±1.0、24.0±1.2和243.4±46.2；细胞毒性T淋巴细胞对前列腺癌细胞的细胞溶解活性分别为(14.6±1.1)%、(15.2±0.8)%和(62.6±2.3)%（P<0.05）。但对于来源于脾脏的T细胞，各组间IFN-γ+CD4+ Th细胞或CTL的细胞溶解活性无差异。治疗后第28天，DLN转移率分别为100%、80%和40%。肺转移率均为100%。
前列腺癌冷冻消融可诱导抗肿瘤免疫的Th1优势，并在DLN中产生肿瘤特异性免疫反应。但该反应仍然有限。有必要进一步研究。
